Study of EPI-001 in Patients With Androgenetic Alopecia
Recruiting
Phase 1
Phase 2
Interventional Study
Androgenetic Alopecia
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 42 (estimated)
- Sponsor
- Epibiotech · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.
In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration.
In the P…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Male or female subjects aged 19 years or older
2. Subjects diagnosed with androgenetic alopecia
3. Subjects willing to maintain the same hairstyle, hair length, and hair color during the study period
4. Subjects willing to refrain from prohibited hair-related products or proc…
Contacts